Subgroup outcomes from RAISE: A randomized, Phase 3 trial of zilucoplan in generalized myasthenia gravis

被引：0
|
作者：
Weiss, Michael D. [1 ]
Bresch, Saskia [2 ]
Freimer, Miriam [3 ]
Hewamadduma, Channa [4 ]
Juntas-Morales, Raul [5 ]
Leite, M. Isabel [6 ]
Maniaol, Angelina [7 ]
Masuda, Masayuki [8 ]
Sivakumar, Kumaraswamy [9 ]
Zajda, Malgorzata [10 ]
Boroojerdi, Babak [11 ]
Duda, Petra W. [12 ]
De La Borderie, Guillemette [13 ]
Howard, James F., Jr. [14 ]
机构：
[1] Univ Washington, Med Ctr, Dept Neurol, Seattle, WA USA
[2] Ctr Hosp Univ Nice, Nice, France
[3] Ohio State Univ, Columbus, OH USA
[4] Univ Sheffield, Dept Neurosci, Sheffield, S Yorkshire, England
[5] Vall dHebron Univ Hosp, Barcelona, Spain
[6] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford, England
[7] Oslo Univ Hosp, Dept Neurol, Oslo, Norway
[8] Tokyo Med Univ, Dept Neurol, Tokyo, Japan
[9] Univ Arizona, Sch Med, Neuromuscular Clin & Res Ctr, Tucson, AZ USA
[10] Med Univ Warsaw, Warsaw, Poland
[11] UCB Pharma, Monheim, Germany
[12] UCB Pharma, Cambridge, MA USA
[13] UCB Pharma, Brussels, Belgium
[14] Univ N Carolina, Dept Neurol, Chapel Hill, NC USA
来源：
NEUROLOGY | 2023年 / 100卷 / 17期
关键词：
D O I：
10.1212/WNL.0000000000202904
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1-5.006
引用
收藏
页数：5
相关论文
共 50 条
  • [31] VIVACITY MG PHASE 3 STUDY: CLINICAL TRIAL OF NIPOCALIMAB ADMINISTERED TO ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
    Ramchandren, Sindhu
    Sanga, Panna
    Burcklen, Michel
    Sun, Hong
    MUSCLE & NERVE, 2022, 66 : S51 - S51
  • [32] Vivacity MG Phase 3 Study: Clinical Trial of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    Ramchandren, S.
    Sanga, P.
    Burcklen, M.
    Sun, H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 299 - 299
  • [33] Vivacity MG Phase 3 Study: Clinical Trial of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    Ramchandren, Sindhu
    Sanga, Panna
    Burcklen, Michel
    Sun, Hong
    NEUROLOGY, 2022, 99 (23) : S41 - S41
  • [34] Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study
    Howard Jr, James F.
    Bresch, Saskia
    Farmakidis, Constantine
    Freimer, Miriam
    Genge, Angela
    Hewamadduma, Channa
    Hinton, John
    Hussain, Yessar
    Juntas-Morales, Raul
    Kaminski, Henry J.
    Maniaol, Angelina
    Mantegazza, Renato
    Masuda, Masayuki
    Nowak, Richard J.
    Sivakumar, Kumaraswamy
    Smilowski, Marek
    Utsugisawa, Kimiaki
    Vu, Tuan
    Weiss, Michael D.
    Zajda, Malgorzata
    Bloemers, Jos
    Boroojerdi, Babak
    Brock, Melissa
    de la Borderie, Guillemette
    Duda, Petra W.
    Vanderkelen, Mark
    Leite, M. Isabel
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2024, 17
  • [35] TREATMENT OUTCOMES AMONG PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS IN THE CZECH REPUBLIC: RESULTS FROM MYASTHENIA GRAVIS REGISTRY (MYREG)
    Vohanka, Stanislav
    Tyblova, Michaela
    Horakova, Magda
    Cai, Qian
    Kwong, Winghan
    Gandhi, Kavita
    Batista, Alberto E.
    Baranova, Jana
    Mokra, Lenka
    Tyblova, Michaela
    Junkerova, Jana
    Ehler, Edvard
    Matulova, Hana
    Mazanec, Radim
    Ridzon, Petr
    Kavanagh, Shane
    MUSCLE & NERVE, 2024, 70 (03) : 515 - 516
  • [36] RAISE-XT: An interim analysis of safety and efficacy in an open-label extension study of zilucoplan in patients with myasthenia gravis
    Freimer, Miriam
    Leite, M. Isabel
    Genge, Angela
    Hussain, Yessar
    Kaminski, Henry J.
    Mantegazza, Renato
    Utsugisawa, Kimiaki
    Vu, Tuan
    Duda, Petra W.
    Boroojerdi, Babak
    Vanderkelen, Mark
    Lowcock, Romana
    Howard, James F., Jr.
    NEUROLOGY, 2023, 100 (17)
  • [37] Response to rozanolixizumab in patients with generalized myasthenia gravis (gMG) from the Phase 3 MycarinG study
    Vissing, J.
    Druzdz, A.
    Grosskreutz, J.
    Habib, A.
    Mantegazza, R.
    Utsugisawa, K.
    Vu, T.
    Grimson, F.
    Lejdstrom, R. Beau
    Pulido-Valdeolivas, I.
    Tarancon, T.
    Bril, V.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S178 - S179
  • [38] PHASE II TRIAL OF METHOTREXATE IN MYASTHENIA GRAVIS
    Pasnoor, M.
    Herbelin, L.
    He, J.
    Dimachkie, M. M.
    Nations, S.
    Bril, V.
    Wang, A.
    Kissel, J.
    Burns, T.
    Saperstein, D.
    Rosenfeld, J.
    Shaibani, A.
    Jackson, C.
    Swenson, A.
    Howard, J.
    Goyal, N.
    David, W.
    Wicklund, M.
    Pulley, M.
    Benatar, M.
    Pascuzzi, R.
    Genge, A.
    Simpson, E.
    Miller, J.
    Barohn, R. J.
    MUSCLE & NERVE, 2014, 50 (04) : 718 - 718
  • [39] Phase II trial of methotrexate in myasthenia gravis
    Pasnoor, Mamatha
    He, Jianghua
    Herbelin, Laura
    Dimachkie, Mazen
    Barohn, Richard J.
    MYASTHENIA GRAVIS AND RELATED DISORDERS II, 2012, 1275 : 23 - 28
  • [40] PHASE II TRIAL OF METHOTREXATE IN MYASTHENIA GRAVIS
    Barohn, R. J.
    Pasnoor, M.
    Herbelin, L.
    Dimachkie, M.
    MUSCLE & NERVE, 2013, 48 (04) : 690 - 690
12345